Clinical Trials
108 trialsPalbociclib and Cetuximab in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
Inspirna, Inc.
S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
SWOG Cancer Research Network
TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
Roswell Park Cancer Institute
Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer
University of Washington
Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
PAVO
Tempus AI
A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer
NuCana plc
COCHISE
Institut Bergonié
PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
UNC Lineberger Comprehensive Cancer Center
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Neoadjuvant Therapy for Locally Advanced Colon Cancer
Zhejiang University
Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab
TheraOp
Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer
Ohio State University Comprehensive Cancer Center
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
Ohio State University Comprehensive Cancer Center
SPIRIT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Topical Menthol for the Treatment of Chemotherapy Induced Peripheral Neuropathy
Columbia University
Nivolumab in Preventing Colon Adenomas in Participants With Lynch Syndrome and a History of Partial Colectomy
Ohio State University Comprehensive Cancer Center
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
NSABP Foundation Inc
VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
National Cancer Institute (NCI)
Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
National Cancer Institute (NCI)
LODESTAR
pharmaand GmbH
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Eastern Cooperative Oncology Group
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy
Eastern Cooperative Oncology Group
Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
M.D. Anderson Cancer Center
Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers
National Institutes of Health Clinical Center (CC)
PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
Amgen
Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer
Amgen
OMEGA
Institut Bergonié
ABLATE
Imunon
Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors
Fred Hutchinson Cancer Center
Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
SCRI Development Innovations, LLC
FANG-CLM
Gradalis, Inc.
Study of Bevacizumab Combined With Capecitabine and Either Oxaliplatin or Irinotecan as First Course of Treatment for Patients With Colorectal Cancer That Has Spread Beyond the Colon
NSABP Foundation Inc
Memantine Hydrochloride in Helping Cancer Survivors Stop Smoking
Wake Forest University Health Sciences
PIMABI
GERCOR - Multidisciplinary Oncology Cooperative Group
Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
Rutgers, The State University of New Jersey
Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer
Jazz Pharmaceuticals
Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
Maimonides Medical Center
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
Abramson Cancer Center at Penn Medicine
Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan
M.D. Anderson Cancer Center
Enzastaurin for Patients With Metastatic Colorectal Cancer
Eli Lilly and Company
SorCape
University of Florida
Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
Brown University
Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
National Cancer Institute (NCI)
Lymphatic Mapping for Sentinel Node Identification and Analysis
Imperial College London